BamSEC and AlphaSense Join Forces
Learn More

Oragenics Inc. – Material Contracts

NYSE American: OGEN    
Share price (8/4/26): $0.55    
Market cap (8/4/26): $2.482 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 8-K 18 pages Executive Employment Agreement
12/34/56
EX-10.1
from 8-K 43 pages Securities Purchase Agreement
12/34/56
EX-10.27
from S-1/A 43 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 8-K 18 pages Executive Employment Agreement
12/34/56
EX-10.28
from 10-K 12 pages Placement Agency Agreement
12/34/56
EX-10.27
from 10-K 4 pages Oragenics, Inc. - Lock-Up Agreement March 13, 2025
12/34/56
EX-10.26
from 10-K 20 pages Oragenics, Inc. Senior Note
12/34/56
EX-10.25
from 10-K 40 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 2 pages First Amendment to Employment Agreement
12/34/56
EX-10.1
from 8-K 19 pages Executive Employment Agreement
12/34/56
EX-10.1
from 8-K 44 pages Securities Purchase Agreement
12/34/56
EX-10.1
from 10-Q 37 pages Oragenics, Inc. Common Stock (Par Value $0.001 Per Share) At-The-Market Issuance Sales Agreement
12/34/56
EX-10.1
from 8-K 20 pages Executive Employment Agreement
12/34/56
EX-10.6
from 10-Q 32 pages [***] Portions of This Exhibit Have Been Redacted Pursuant to Item 601(b)(2) of Regulations S-K as (I) Not Material and (II) Likely to Cause Competitive Harm if Publicly Disclosed. the Company Hereby Undertakes to Furnish Unredacted Copies of This Exhibit Upon Request by the Securities and Exchange Commission; Provided, However, That the Company May Request Confidential Treatment Pursuant to Rule 24b-2 of the Exchange Act for Such Unredacted Copies of This Exhibit
12/34/56
EX-10.1
from 8-K 5 pages Form of Oragenics, Inc. Restricted Stock Award Grant Notice
12/34/56
EX-10.1
from 8-K 31 pages Securities Purchase Agreement
12/34/56
EX-10.7
from 10-Q 2 pages [***] Portions of This Exhibit Have Been Redacted Pursuant to Item 601(b)(2) of Regulations S-K as (I) Not Material and (II) Likely to Cause Competitive Harm if Publicly Disclosed. the Company Hereby Undertakes to Furnish Unredacted Copies of This Exhibit Upon Request by the Securities and Exchange Commission; Provided, However, That the Company May Request Confidential Treatment Pursuant to Rule 24b-2 of the Exchange Act for Such Unredacted Copies of This Exhibit
12/34/56
EX-10.5
from 10-Q 31 pages [***] Portions of This Exhibit Have Been Redacted Pursuant to Item 601(b)(2) of Regulations S-K as (I) Not Material and (II) Likely to Cause Competitive Harm if Publicly Disclosed. the Company Hereby Undertakes to Furnish Unredacted Copies of This Exhibit Upon Request by the Securities and Exchange Commission; Provided, However, That the Company May Request Confidential Treatment Pursuant to Rule 24b-2 of the Exchange Act for Such Unredacted Copies of This Exhibit
12/34/56
EX-10.1
from 8-K 19 pages Executive Employment Agreement
12/34/56
EX-10.4
from 10-Q 2 pages This Is an Amending Agreement (Hereinafter Referred to as the “Amendment #4”) Between: National Research Council of Canada (Called “Nrc” ) a Departmental Corporation” Forming Part of the Government of Canada, Which Corporation Was Created by Act of Parliament, R.S.C. 1985, C. N-15 Whose Head Office Address Is: 1200 Montreal Road, Ottawa, Ontario K1a 0r6 Canada Human Health Therapeutics (Hht) Research Centre Located At: 6100 Royalmount Avenue, Montreal, Quebec H4p 2r2 Canada
12/34/56